Tagged with API

Singapore Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers in Singapore and beyond, and why Asian representation in clinical trials is of vital importance moving forward.   Technology has…

Switzerland Chief Financial Officer Marina Lugova introduces pharmaceutical company Synbias Pharma’s evolving European footprint, how the company has been able to withstand the COVID-19 pandemic and continue providing its essential products to customers, and its plans for the future, including further investments in the firm’s German production facility and new strategic…

Europe In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved to strengthen its antibiotics manufacturing presence in Austria.   The planned combined investment of EUR 150 million by Sandoz and…

Belgium Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They also tackle some of the criticisms often levelled at parallel distributors and foreground the industry’s vital importance for Belgian, and…

Belgium Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines across Belgium and Europe during the COVID-19 pandemic, rebuffs some of the negative stereotypes that the industry has garnered, and…

India COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing hubs are back in operation.    After over a month of lockdown and significantly reduced manufacturing capacity, the international pharma…

Czech Republic In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working almost 30 years previously.   My goal is to continue reinvesting our profits to keep growing and leave behind a…

Czech Republic Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration…

Czech Republic In 1996, Jiří Žák, chairman & current CEO of FARMAK, took over the state-owned producer of vitamins FARMAKON where he previously worked for 30 years and turned it into a flourishing private company focused on the research, development, and production of active pharmaceutical ingredients (APIs), intermediates, and specialized chemicals. Žák shares the early success…

Taiwan Lily Wu, CEO of PapiVax, discusses the biotechs initiative pipeline for the treatment of HPV related diseases and cancers and goes on to elaborate the company’s development and future partnership strategies. Wu also discusses the unique structure of PapiVax as a lean, R&D and research-driven biotech which is powered by…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

Korea Kukjeon, originally a leading Korean pharmaceutical wholesaler, has in recent years expanded into API manufacturing. Its president, Jay Hong, explains his high-risk strategy to pursue new API business opportunities, and his plan to penetrate global markets from Japan to Europe.   My preferred strategy is to go down the path…